ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.89
0.70%
US Tech 100
18,062.00
-0.10%
S&P 500
5,303.27
0.12%
US Dollar vs CAD
1.36165
-0.01%
Bitcoin
66,919.29
-0.24%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. NextCure Inc (NXTC)

  7. NextCure Inc (NXTC) News

NXTC

NextCure (NXTC)

NextCure Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NXTC
DateTimeSourceHeadlineSymbolCompany
05/02/20243:05PMGlobeNewswire Inc.NextCure Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:NXTCNextCure Inc
04/24/20243:05PMGlobeNewswire Inc.NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024NASDAQ:NXTCNextCure Inc
04/08/20246:00AMGlobeNewswire Inc.NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024NASDAQ:NXTCNextCure Inc
04/04/20246:05AMGlobeNewswire Inc.NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory BoardNASDAQ:NXTCNextCure Inc
04/02/20246:00AMGlobeNewswire Inc.NextCure to Present at 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:NXTCNextCure Inc
03/21/20247:55AMGlobeNewswire Inc.NextCure Provides Business Update and Reports Full Year 2023 Financial ResultsNASDAQ:NXTCNextCure Inc
03/05/20247:05AMGlobeNewswire Inc.NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science AdvancesNASDAQ:NXTCNextCure Inc
02/01/20243:45PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NXTCNextCure Inc
02/01/20243:45PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NXTCNextCure Inc
02/01/20243:44PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NXTCNextCure Inc
02/01/20243:44PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NXTCNextCure Inc
02/01/20243:43PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NXTCNextCure Inc
02/01/20243:43PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NXTCNextCure Inc
01/18/20243:05PMGlobeNewswire Inc.NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway DisordersNASDAQ:NXTCNextCure Inc
12/21/20236:05AMGlobeNewswire Inc.NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord InjuryNASDAQ:NXTCNextCure Inc
12/14/20236:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NXTCNextCure Inc
12/14/20235:45AMGlobeNewswire Inc.NextCure Provides Year-End Clinical Pipeline UpdatesNASDAQ:NXTCNextCure Inc
11/20/20236:00AMGlobeNewswire Inc.NextCure to Present at the 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:NXTCNextCure Inc
11/15/20233:05PMGlobeNewswire Inc.NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AMLNASDAQ:NXTCNextCure Inc
11/02/20233:20PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NXTCNextCure Inc
11/02/20233:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NXTCNextCure Inc
11/02/20233:05PMGlobeNewswire Inc.NextCure Provides Business Update and Reports Third Quarter 2023 Financial ResultsNASDAQ:NXTCNextCure Inc
10/17/20237:05AMGlobeNewswire Inc.Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)NASDAQ:NXTCNextCure Inc
09/26/20233:05PMGlobeNewswire Inc.NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s DiseaseNASDAQ:NXTCNextCure Inc
09/12/20237:05AMGlobeNewswire Inc.A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLCNASDAQ:NXTCNextCure Inc
09/07/20233:05PMGlobeNewswire Inc.NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor CollagenNASDAQ:NXTCNextCure Inc
09/05/20233:05PMGlobeNewswire Inc.Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone DiseaseNASDAQ:NXTCNextCure Inc
08/31/20236:00AMGlobeNewswire Inc.NextCure to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:NXTCNextCure Inc
08/04/20233:58PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NXTCNextCure Inc
08/04/20233:30PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:NXTCNextCure Inc
 Showing the most relevant articles for your search:NASDAQ:NXTC

Your Recent History

COIN
SALTTTUST
SALT Coin
HUOB
BORGUSDT
SwissBorg
EU
U245S
U245S
EU
P933S
P933S
USOTC
PHGEW
Biomx (PK)
EU
C6RI
CAC Large 60 Responsible...
COIN
NEXOEUR
Nexo
ASI
FTSE_TT
FTSE Athex Technology & ...
EU
R214S
R214S
ASX
PEKND
Peak Rare Earths
BIT
F00SPX
Vontobel Financial Produ...
KOSPI
017960
Hankuk Carbon
BIT
UR9ZPF
UniCredit Bank
LSE
MIX
Mobeus Income & Growth Vct
NASDAQ
SNAL
Snail
NASDAQI
OMXI15GI
OMX Iceland 15 GI
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved